Valuation Edwards Lifesciences Corporation
Stocks
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.62 USD | -0.13% |
|
-6.67% | +0.49% |
| 07-16 | Truist Adjusts Price Target on Edwards Lifesciences to $95 From $90, Maintains Hold Rating | MT |
| 07-16 | Abbott raises 2026 profit forecast on heart device strength | RE |
Company Valuation: Edwards Lifesciences Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,883 | 46,128 | 46,246 | 43,663 | 49,471 | 49,363 | - | - |
| Change | - | -42.97% | 0.25% | -5.58% | 13.3% | -0.22% | - | - |
| Enterprise Value (EV) 1 | 80,616 | 45,956 | 45,198 | 40,285 | 45,843 | 46,086 | 44,393 | 42,450 |
| Change | - | -42.99% | -1.65% | -10.87% | 13.8% | 0.53% | -3.67% | -4.38% |
| P/E | 54.4x | 30.6x | 33.2x | 10.6x | 46.6x | 30.6x | 26.2x | 23.4x |
| PBR | 13.9x | 7.82x | 6.99x | 4.36x | 4.79x | 4.51x | 4.1x | 3.91x |
| PEG | - | 12.14x | -5.79x | 0x | -0.6x | 0.6x | 1.6x | 1.9x |
| Capitalization / Revenue | 15.5x | 8.57x | 7.7x | 8.03x | 8.15x | 7.32x | 6.67x | 6.07x |
| EV / Revenue | 15.4x | 8.54x | 7.53x | 7.41x | 7.56x | 6.83x | 5.99x | 5.22x |
| EV / EBITDA | 46.6x | 23.7x | 24.1x | 24.1x | 25.5x | 21.8x | 18.8x | 15.9x |
| EV / EBIT | 50.6x | 25.6x | 26.1x | 26.6x | 27.9x | 23.6x | 20.3x | 17.3x |
| EV / FCF | 57.3x | 47.2x | 47.9x | 139x | 34.3x | 33.8x | 26.2x | 21.9x |
| FCF Yield | 1.74% | 2.12% | 2.09% | 0.72% | 2.91% | 2.96% | 3.82% | 4.56% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 2.38 | 2.44 | 2.3 | 6.97 | 1.83 | 2.804 | 3.273 | 3.671 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5,232 | 5,382 | 6,005 | 5,440 | 6,068 | 6,743 | 7,405 | 8,132 |
| EBITDA 1 | 1,729 | 1,936 | 1,879 | 1,670 | 1,800 | 2,114 | 2,365 | 2,670 |
| EBIT 1 | 1,594 | 1,796 | 1,734 | 1,514 | 1,644 | 1,956 | 2,190 | 2,456 |
| Net income 1 | 1,503 | 1,522 | 1,402 | 4,175 | 1,074 | 1,618 | 1,881 | 2,098 |
| Net Debt 1 | -267 | -172.7 | -1,048 | -3,378 | -3,628 | -3,278 | -4,970 | -6,914 |
| Reference price 2 | 129.55 | 74.61 | 76.25 | 74.03 | 85.25 | 85.73 | 85.73 | 85.73 |
| Nbr of stocks (in thousands) | 624,334 | 618,260 | 606,500 | 589,800 | 580,300 | 575,800 | - | - |
| Announcement Date | 1/26/22 A | 1/31/23 A | 2/6/24 A | 2/11/25 A | 2/10/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 30.57x | 6.83x | 21.8x | -.--% | 49.36B | |
| 26.66x | 4.79x | 18.41x | 0.35% | 198B | |
| 32.98x | 6.37x | 20.04x | 0.7% | 144B | |
| 37.55x | 9.83x | 21.78x | -.--% | 122B | |
| 16.19x | 3.34x | 10.77x | -.--% | 65.44B | |
| 18.62x | 2.14x | 11.1x | 2.82% | 44.74B | |
| 25.56x | 5.09x | 17.4x | 0.78% | 37.13B | |
| 44.72x | 6.25x | 19.21x | -.--% | 36.23B | |
| 18.8x | 4.94x | 12.74x | 1.22% | 28.7B | |
| 14.18x | 1.58x | 8.81x | 0.23% | 28.69B | |
| Average | 26.58x | 5.12x | 16.21x | 0.61% | 75.48B | |
| Weighted average by Cap. | 28.54x | 5.73x | 17.80x | 0.49% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EW Stock
- Valuation Edwards Lifesciences Corporation
Select your edition
All financial news and data tailored to specific country editions
